

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

Ongoing	
All Day	
	<p>Exhibition Booth: “Microbicides, Vaccines and more: Partners in Prevention Research Advocacy”</p> <p>Summary: AVAC, AMAG, GCM & NHVMAG collaborating on a site for daily events – speakers; meet the organizations; issue briefs; etc. on AIDS vaccines and prevention research.</p> <p>Location: Area G. Booth 482</p>
Ongoing	
All Day	
	<p>Networking Zone: “New Prevention Technologies Networking Zone”</p> <p>Summary: A space in the Global Village where advocates, community members and researchers can gather together to discuss current issues involved in prevention research</p> <p>Location: Global Village (booths 1041 and 1043)</p>
Saturday 12	
08:30-14:30	
	<p>Satellite Session: “The Intersection of Cutting-Edge Social, Behavioral and Biomedical Strategies for HIV Prevention”</p> <p>Summary: Symposium designed to initiate a discourse on the unique role social and behavioral science will play in improving the acceptability, accessibility, adherence, sustainability, and robustness of new biomedical strategies (e.g., male circumcision, microbicides, pre-exposure prophylaxis). To register: http://chipts.ucla.edu/onlineereg/August1206/index.asp</p> <p>Location: Radisson Admiral – Toronto Harbor front</p>
Saturday 12	
13:00-18:00	
	<p>Satellite Session: “Partnerships for the future: AIDS vaccine research in the developing world”</p> <p>Summary: IAVI, AVAC and others are co-sponsoring this session on AIDS vaccine research capacity in low and middle income countries. More information at http://www.iavi.org/viewpage.cfm?aid=1413</p> <p>Location: Renaissance Toronto Hotel</p>
Sunday 13	
10:15-12:15	
	<p>Satellite Session: “Almost Everything You Ever Wanted to Know About Vaccinology: A Short Course on How Vaccines Work”</p> <p>Summary: Foundation Mérieux, SanofiPasteur and AVAC are co-sponsoring this primer on how vaccines work, basic principles to help media and community advocates understand vaccine development. Jose Esparza of the Gates Foundation will present an update on the recent Foundation grants to support the Global Enterprise.</p> <p>Presenters: Jose Esparza, Stanley Plotkin, Huntly Collins, and Mitchell Warren</p> <p>Location: Skills Building Room 8</p>
Sunday 13	
10:15-12:15	
	<p>Satellite Session: Contraceptive Technologies: More Choices, Better Options</p> <p>Summary: Research related to HIV, women’s health and effective contraception currently takes place in separate, non-overlapping spheres. This symposium will explore critical issues related to providing contraception for women and families affected by HIV.</p> <p>Location: Skills Building Room 5</p>

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

Sunday 13	
12:30-14:30	
	<p>Title: "Viral Load: A Surrogate Marker for AIDS Vaccine Efficacy" Summary: This satellite symposium will explore the issues and status behind using viral load as a surrogate marker for vaccine efficacy. Presenters: Lawrence Corey; Ronald Veazey; Sally Blower; Tom Quinn. Location: Skills Building Room 7</p>
Sunday 13	
13:00-14:30	
	<p>Global Village Community Forum: "Everything you ever wanted to know about AIDS vaccines", sponsored by AVAC. Summary: Learn about AIDS vaccines, clinical trial process, and find out who is doing what and where. Among topics to be discussed are: benefits and limitations of vaccines, key areas for community advocacy and concrete examples for action. Location: Global Village Session Hall 1</p>
Sunday 13	
14:45-16:45	
	<p>Satellite: "What if pre-exposure prophylaxis (PrEP) works?" Presenters: International AIDS Society Location: Skills Building Room 6</p>
Sunday 13	
14:45-16:45	
	<p>Satellite Session: "The Potential Role of HPV Vaccines in Improving HIV Prevention among Young Girls and Women" Summary: UNFPA and WHO are co-sponsoring this session; AVAC presenting on the connections between HPV and HIV vaccines, especially in terms of adolescent issues. Location: Skills Building Room 9</p>
Monday 14	
10:45-12:15	
	<p>Skills Building: "Towards a new GCP: 'Good Community Practice' in prevention research" Summary: AVAC sponsored interactive workshop will provide an opportunity to explore ways to more meaningfully engage communities in the search for new prevention options. By the end of the session, the participants will contribute to new ways of understanding, creating and sustaining authentic community involvement in the research process. Location: Skills Building Room 1</p>
Monday 14	
13:10-13:45	
	<p>Poster Discussion: "Distributing barrier methods for women: determinants of willingness to pay for microbicides, the diaphragm and the female condom" Presenters: Terris-prestholt F, Kumaranayake L, Macphail C, Rees H, Watts C Location: Poster Discussion Site C</p>
Monday 14	
18:00-20:00	
	<p>Satellite Session: "Female Condoms: beyond funds what would it take to upscale programmes at the country level?" Summary: UNFPA sponsored satellite that explores programmatic issues that need to be put in place in order for scaling up introduction of new technologies. Location: Room 7</p>

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

<p>Tuesday 15 07:00-08:30</p>	<p>Satellite Session: “Community Matters: Engaging, Mobilizing and Sustaining Community Involvement in HIV vaccine and prevention research.” (Breakfast Provided!) Summary: AVAC’s work/priorities/agenda – who we are & what we’re planning – and what’s follow-on from Barcelona advocates’ meeting. Also, a discussion about community involvement in the Global HIV Vaccine Enterprise. Presenters: AVAC, Bill & Melinda Gates Foundation, Global HIV Vaccine Enterprise Location: Room 8</p>
<p>Tuesday 15 08:45-10:15</p>	<p>Plenary Session: “Prevention: Proven Approaches and New Technologies” Summary: This plenary session includes updates on prevention efforts generally, and specific presentations on microbicides, vaccines and other new prevention technologies. Presenters: Gita Ramjee on “Microbicides and Other New Prevention Technologies” and Françoise Barré-Sinoussi on “Dynamics of HIV/AIDS Vaccine Research” Location: Room 1</p>
<p>Tuesday 15 10:45-12:15</p>	<p>Oral Abstract Session: “Male Circumcision: Is it Time To Act?” Presentations include:</p> <ul style="list-style-type: none"> • A randomized controlled trial of male circumcision to reduce HIV incidence in Kisumu, Kenya: progress to date (Bailey et al) • Male circumcision and HIV infection risk among tea plantation residents in Kericho, Kenya: incidence results after 1.5 years of follow-up (Sateren et al) • Potential benefits of expanded male circumcision programs in Africa: predicting the population-level impact on heterosexual HIV transmission in Soweto (Mesesan et al) • Cost-effectiveness of male circumcision in sub-Saharan Africa (Kahn et al) • Male circumcision in Siaya and Bondo districts, Kenya: a prospective cohort study to assess behavioural disinhibition following circumcision (Agot et al) <p>Location: Session Room 5</p>
<p>Tuesday 15 12:30-14:00</p>	<p>Poster Presentations:</p> <ul style="list-style-type: none"> • Towards a new GCP: “Good Community Practice” in prevention research (AVAC) • Modeling Phase III Microbicide Clinical Trial Costs (International Partnership for Microbicides) • Ethical Challenges for HIV Prevention Trials in Africa: The cultural meaning of pill-taking and local research literacy in Tema, Ghana (Family Health International) • Factors influencing adherence to Pills for Pre-exposure Prophylaxis: Lessons learnt from phase 2 trial in Nigeria (Family Health International) • Building Public Support for Microbicides in Europe and North America (Global Campaign for Microbicides) • Rectal microbicides in demand: engaging men and women in rectal microbicides advocacy (Health Canada) • Analytical Overview of Microbicide Pipeline (Alliance for Microbicide Development) • The Development of the Canadian Microbicides Action Plan as a Model of Multi-Sectoral Collaboration (Government of Canada) • Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials (Population Council)

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

Tuesday 15 12:45-12:50	<p>Poster Discussion: "Evaluation of microbicide applicators to determine vaginal use in the Carraguard phase 3 clinical trial" Presenters: Govender et al Location: Key Challenge Area 1</p>
Tuesday 15 14:15-15:45	<p>Symposium: "A world without AIDS: The long road to effective HIV vaccines" Summary: Mitchell Warren and Peggy Johnston are co-chairing this non-abstract session, scheduled to include presentations that 1. Review scientific obstacles to HIV vaccine development, 2. Analyze the challenges in developing HIV vaccines from an industry perspective, 3. Review issues related to community involvement in HIV vaccine development, and 4. Examine how the Enterprise can help to address some of the challenges surrounding HIV vaccines. Location: Room 2</p>
Tuesday 15 14:15-15:45	<p>Oral Abstract Session: "Tracking the Epidemic: Modeling and Methodological Issues" Sub-Presentation:</p> <ul style="list-style-type: none"> • Four cities modelling: #2 the dynamic impact of male circumcision and curable STIs on the heterogeneity of HIV epidemics in sub-Saharan Africa - simulation results (Orroth et al)
Tuesday 15 16:15-17:45	<p>Oral Abstract Session: "Ethical Issues in Clinical Trials: Tenofovir and Beyond" Presentations include:</p> <ul style="list-style-type: none"> • Making the ethical feasible: assuring future access to care to those who sero-convert in microbicide trials (Forbes, A.) • Revisiting the ethics of HIV prevention research in developing countries (Weijer C., LeBlanc G.) • Overcoming the challenges of prevention research: lessons learned from the tenofovir pre-exposure prophylaxis trials (Halima, Y.) • Beyond the checklist: assessing understanding of participation in HIV vaccine trials in South Africa (Lindegger et al) • Influencing legislative processes and policy development in order to improve research ethics (Fischer H, Fabrice P) <p>Location: Session Room 12</p>
Tuesday 15 18:30-20:00	<p>Global Village Community Forum: "Research with Marginalized Populations: Authentic Community Involvement and Engagement" Summary: This session will explore how best to meaningfully and authentically engage and involve members from marginalized populations in HIV research. The program is in conjunction with the International Network of Sex Work Projects and a sex worker organization in Montreal. Location: Global Village Session Hall 2</p>

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

Tuesday 15	
18:30-20:00	<p>Global Village Community Forum: “New Prevention Technologies: vaccines, microbicides and cervical barriers”</p> <p>Summary: Session will provide an overview of the latest developments in new prevention technologies, including research, policy development and advocacy in vaginal and rectal microbicides, vaccines, pre-exposure prophylaxis and cervical barriers. The Canadian AIDS Society, Microbicide Advocacy Group Network, Global Campaign for Microbicides, AIDS Committee of Toronto, AVAC.</p> <p>Location: Global Village Session Hall 1</p>
Wednesday 16	
12:45-13:45	<p>Poster Discussion: “Accelerating Research: Approaches that Work”</p> <p>Discussion: Adding it all up: funding for HIV vaccine and microbicide research and development between 2000 and 2005 (Fisher et al)</p> <p>Location: Key Challenge Area 1</p>
Wednesday 16	
14:15-17:45	<p>Skills building: “Count the Benefits: Modeling the Impacts of AIDS Vaccines in a Comprehensive Response to HIV/AIDS”</p> <p>Summary: WHO, UNAIDS and IAVI joint skills-building session to provide a demonstration of new tools for modeling the potential epidemiological impacts of future AIDS vaccines (and of other prevention methods). Two new computer models project the course of the epidemic into the future with and without the potential benefits of vaccines.</p> <p>Location: Skills Building Room 11</p>
Wednesday 16	
16:15-17:45	<p>Oral Abstract Session: “Microbicide Development”</p> <p>Presentations include:</p> <ul style="list-style-type: none"> • Invited Presentation: Overview of Microbicide Development (Robin Shattock) • Characterization of in vitro release and in vivo delivery of TMC120 with an intravaginal ring: implications for microbicide delivery (Romano et al) <p>Location: Session Room 9</p>
Thursday 17	
10:45-12:15	<p>Oral Abstract Session: “Late Breaker Track C”</p> <p>Presentations include:</p> <ul style="list-style-type: none"> • Low levels of pre-exposure prophylaxis awareness and use among HIV-negative/unknown gay/bisexual men: San Francisco Bay Area residents, circuit party attendees, and clients of an urban STD clinic (Liu A et al) • Cost-effectiveness analysis of HIV chemoprophylaxis (Grant R et al) • Findings from a double-blind, randomized, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women (Peterson L et al) <p>Location: Session Room 12</p>

Vaccines, Microbicides and New Prevention Technologies, XVI IAC, Toronto, August 2006

Thursday 17 11:45-12:15	Oral Abstract Session: "Resistance - Before you Start HAART" Presentations include: <ul style="list-style-type: none">• Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach (Smith et al) Location: Session Room 9
Thursday 17 14:15-15:45	Oral Abstract Session: Vaccine Research Presentations include: <ul style="list-style-type: none">• Knowledge and attitudes about HIV vaccine research among health workers in two provinces in Kenya (Kalibala et al)• Use of conjoint analysis methods to assess HIV vaccine acceptability in three populations: an innovation in the assessment of consumer healthcare preferences (Lee S-J et al)• Seven points of entry for ACTION - microbicides, vaccines and treatment (MTV) advocates agenda (Mellors S, Cavanaugh D)• Differences in willingness to pay for an AIDS vaccine in Uganda (Patil P, Bishai D)• Location: Session Room 12
Thursday 17 14:45-16:15	Panel Discussion: Choices for Women: Promoting Investment in Multiple Female Initiated or Controlled HIV Prevention Methods Description: There has been increased attention to the impact of AIDS on women and girls and the urgent need for female-initiated and –controlled methods to address current prevention gaps. Vaccines or microbicides would be significant options alone, though existing methods, including the female condom, and other methods with potential for preventing transmission of HIV, such as cervical barriers, would augment their effectiveness. Location: Women's Networking Zone, Global Village